A straightforward meta-analysis approach for oncology phase I dose-finding studies

Abstract

Phase I early-phase clinical studies aim at investigating the safety and the underlying dose-toxicity relationship of a drug or combination. While little may still be known about the compound's properties, it is crucial to consider quantitative information available from any studies that may have been conducted previously on the same drug. A meta-analytic approach has the advantages of being able to properly account for between-study heterogeneity, and it may be readily extended to prediction or shrinkage applications. Here we propose a simple and robust two-stage approach for the estimation of maximum tolerated dose(s) (MTDs) utilizing penalized logistic regression and Bayesian random-effects meta-analysis methodology. Implementation is facilitated using standard R packages. The properties of the proposed methods are investigated in Monte-Carlo simulations. The investigations are motivated and illustrated by two examples from oncology.

arXiv comment30 pages, 11 figures, 8 tables

References in corpus (10)

• Firth's logistic regression with rare events: accurate effect estimates AND predictions?
• Bayesian random-effects meta-analysis using the bayesmeta R package
• On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis
• Model-based dose finding under model uncertainty using general parametric models
• Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases
• Dynamically borrowing strength from another study through shrinkage estimation
• A Bayesian time-to-event pharmacokinetic model for sequential phase I dose-escalation trials with multiple schedules
• Using phase II data for the analysis of phase III studies: an application in rare diseases
• Bounds for the weight of external data in shrinkage estimation
• Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors